Impact of Betaine on Hepatic Fibrosis and Homocysteine in Nonalcoholic Steatohepatitis

Table 1: Baseline and End of Treatment Characteristics of 35 Patients with Nonalcoholic Steatohepatitis Treated with Betaine

	BASELINE	END OF TREATMENT	p value
Weight (kilograms)	97.2 +/- 3.15	97.4 +/- 3.63	NS
ALT (U/L)	109 +/- 14.4	45 +/- 10.8	p < 0.05
AST (U/L)	98.1 +/- 21.2	36.9 +/- 5.9	p < 0.05
Alk phos (U/L)	122 +/- 13.7	101 +/- 14.6	p < 0.05
Bilirubin (mg/dl)	0.6 +/- 0.1	0.49 +/- 0.05	p < 0.05
Homocysteine (micromoles/L)	7.72 +/- 0.37	7.42 +/- 0.42	NS
Steatosis	2.28 +/- 0.12	1.13 +/- 0.15	p < 0.05
Inflammation	1.31 +/- 0.12	0.71 +/- 0.11	p < 0.05
Fibrosis	2.09 +/- 0.24	1.29 +/-0.24	p < 0.05

ALT: alanine aminotransferase; AST: aspartate aminotransferase; Alk phos: alkaline phosphatase; NS: not significant. Data expressed as means +/- standard deviation.